Allogene Therapeutics, Inc. · NASDAQ:ALLO

Allogene Therapeutics — ICML 2023

13 slides from Allogene Therapeutics's conference presentation, June 2023

  1. Slide 1: Durable Responses With Anti-CD19 Allogeneic CAR T ALLO-501/ALLO-501A in r/r LBCL

    Durable Responses With Anti-CD19 Allogeneic CAR T ALLO-501/ALLO-501A in Phase 1 Trials of Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Locke FL,1 Lekakis LJ,2 Eradat HA,3 Munoz J,4 Tees M,5 de Vos S,6 Nath R,7 Stevens DA,8 Malik SA,9 Popplewell LL,10 Hamadani M,11 Oluwole OO,12 Perales M-A,1

  2. Slide 2: Conflict of Interest (COI) Disclosures

    Conflict of Interest (COI) Disclosures Locke FL Oluwole OO Consultant/Advisor: A2 Bio, Allogene Therapeutics, Amgen, Bluebird Bio, BMS/Celgene, Consultant/Advisor: Abbvie, ADC Therapeutics, Curio Science, Gilead, Janssen, Kite Pharma, Calibr, Caribou, Cellular Biomedicine Group, Cowen, Daiichi Sanky

  3. Slide 3: Conflict of Interest (COI) Disclosures

    Conflict of Interest (COI) Disclosures de Vos S Kai K Consultant/Advisor: Beigene - Data Safety Advisory Board Employment/Leadership: Allogene Therapeutics, Nektar Therapeutics Nath R Stock ownership: Allogene Therapeutics Consultant/Advisor: Actinium, Incyte Balakumaran A Honoraria: Actinium, Incyt

  4. Slide 4: Background

    Background • Autologous anti-CD19 CAR T cell therapies have revolutionized the treatment of r/r LBCL. Despite this, these therapies are not available to all eligible patients due to lengthy and cumbersome manufacturing processes • ALLO-501A, an allogeneic anti-CD19 CAR T cell product made from healt

  5. Slide 5: Study Subgroup and Schema

    Study Subgroup and Schema • Two Phase 1, open-label, multicenter studies of ALLO-501 and ALLO-501A (ALPHA and ALPHA2a) in patients with r/r NHL were conducted • Subgroup for analysis: 33 CAR T-naïve patients with r/r LBCL treated with escalating doses of ALLO-501/ALLO-501A manufactured with the Phas

  6. Slide 6: Patient Disposition

    Patient Disposition All CAR T-Naïve Pts With r/r LBCL Who Received ALLO-501/ALLO-501A Manufactured With Phase 2 Process N = 33 FCA90 + Single-Dose ALLO-501/ALLO-501A FCA<90 + Single-Dose ALLO-501/ALLO-501A Consolidation N = 12a N=6 ALLO-501/ALLO-501A N = 15 ALLO-501: n=6 ALLO-501: n=5 ALLO-501: n=3

  7. Slide 7: Study Population and Treatment Experience

    Study Population and Treatment Experience Baseline Characteristics of CAR T-Naïve All Phase 2 Regimenb FCA<90 Consolidation Patients With r/r LBCLa (N=33) (N=12)​ (N = 6) (N = 15) Age (years), median 66 60​ 63 67 Stage IV disease (%) 58 67 67 47 ECOG PS of 1​ (%) 79 92​ 50 80 Baseline LDH > ULN (%)

  8. Slide 8: Safety and Tolerability

    Safety and Tolerability CAR T-Naïve Patients With r/r LBCL All Phase 2 Regimen FCA<90 Consolidation (N = 33) (N = 12) (N = 6) (N = 15) Adverse Events All Gr Gr ≥3 All Gr Gr ≥3 All Gr Gr ≥3 All Gr Gr ≥3 of Interest n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) CRS 8 (24) 0 4 (33) 0 1 (17) 0 3 (20)

  9. Slide 9: Efficacy: Response Rates

    Efficacy: Response Rates CAR T-Naïve Patients With r/r LBCL Phase 2 Regimen FCA<90 Consolidation All (N=33) (N=12) (N = 6) (N = 15) ORR, n (%) 19 (58) 8 (67) 3 (50) 8 (53) CR, n (%) 14 (42) 7 (58) 1 (17) 6 (40) 6 months CR,a n (%) 10 (30) 5 (42) 0 5 (33) • Overall response rate was similar across re

  10. Slide 10: Durable Remissions in Patients Who Received ALLO-501/ALLO-501A

    Durable Remissions in Patients Who Received ALLO-501/ALLO-501A Patients With CR (n=14) Durable responses were observed in patients who received lymphodepletion regimens containing 90 mg of ALLO-647 • Overall and Phase 2 Regimen median DOR was 23.1 months • 30% (10/33) of patients had a CR lasting ≥

  11. Slide 11: CAR T Cell Expansion Is Associated With Response

    CAR T Cell Expansion Is Associated With Response Day 1–28 AUCa CAR T Kinetics 10 5 Non-Responders 10 4 Responders Copies / ug DNA 10 3 10 2 10 1 10 0 10 -1 n=8 n=19 0 20 40 60 100 150 200 DayVisit 1–28Day AUC# b AUC = area under the curve; p = 0.0000554 by unpaired t-test. a 6 subjects excluded from

  12. Slide 12: Recovery of Leukocyte Counts

    Recovery of Leukocyte Counts ANC ALC • Neutrophils recovereda at a median of 7 days after ALLO-501/ALLO-501A • Lymphocytes recovereda at a median of 17.5 days after ALLO-501/ALLO-501A • T and NK cells recovered T Cell Counts NK Cell Counts to baseline levels within 6–9 months post-infusion ALC = abs

  13. Slide 13: Conclusions

    Conclusions 1. ALLO-501/ALLO-501A, an off-the-shelf, anti-CD19 allogeneic CAR T cell product, expands, persists and generates durable complete responses in patients with r/r LBCL. 2. Efficacy was observed with all treatment regimens, however, benefit:risk and convenience appeared optimal with the re

Allogene Therapeutics — ICML 2023 on 6ix